<DOC>
	<DOCNO>NCT00660088</DOCNO>
	<brief_summary>AC-1202 ( Ketasyn ) nutritional beverage currently study neurodegenerative condition include Alzheimer 's disease . The current study randomize , open-label trial compare safety , tolerability , PK profile 3 formulation Ketasyn administer daily basis 14 day , without 7-day titration period , normal , healthy elderly volunteer .</brief_summary>
	<brief_title>Safety Three Formulations Ketasyn Administered 14 Days Healthy Elderly</brief_title>
	<detailed_description>Sixty healthy , elderly volunteer age 55 85 enrol one four clinical site Tampa/St . Petersburg area . Subjects history GI inflammatory condition ( e.g. , IBS diverticulitis ) clinically significant abnormality exclude enrollment . Subjects randomize one two dosing regimen ( without 7-day titration period ) one three formulation Ketasyn contain identical amount active ingredient , different amount proteins carbohydrate . Subjects assign Group 1 receive 10 gram active ingredient daily Days 1-7 , follow daily dose 20 gram active ingredient Days 8-14 . Subjects assign Group 2 receive 20 gram active ingredient Days 1-14 . All subject clinic visit Day 1 14 ; subject assign Group 1 also clinic visit Day 8 . Subjects fast prior clinic visit vital sign routine lab test perform prior dosing . A standard breakfast serve along study product , follow blood sample collect product concentration level .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>No clinically significant abnormal finding physical exam , vital sign , medical history , ECG , laboratory result Type 1 uncontrolled Type 2 diabetes History current inflammation GI system , e.g . IBS , diverticular disease , gastric duodenal ulcer , severe GERD require daily medication History ( within past 60 day ) infection Clinically significant renal , hepatic , hematologic abnormality</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>